Wachtell, Kristian

Publications

Sort by

Co-Author Network

selected publications

On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Blood pressure. 2020 Academic Article GET IT
Times cited: 2
Medical Therapies for Heart Failure With Preserved Ejection Fraction. Hypertension (Dallas, Tex. : 1979). 2019 Review GET IT
Times cited: 14
Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study. Blood pressure. 2016 Academic Article GET IT
Times cited: 13
An age-old test in old age: ECG left ventricular hypertrophy and cardiovascular outcomes in the elderly. Journal of hypertension. 2016 Editorial Article GET IT
Times cited: 1
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. Journal of hypertension. 2015 Academic Article GET IT
Times cited: 34
Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study. Hypertension (Dallas, Tex. : 1979). 2015 Academic Article GET IT
Times cited: 18
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. Journal of hypertension. 2015 Academic Article GET IT
Times cited: 10
Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. Hypertension (Dallas, Tex. : 1979). 2015 Academic Article GET IT
Times cited: 44
Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure. Journal of hypertension. 2014 Academic Article GET IT
Times cited: 3
Resting heart rate and risk of adverse cardiovascular outcomes in asymptomatic aortic stenosis: the SEAS study. International journal of cardiology. 2014 Academic Article GET IT
Times cited: 8
Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. International journal of cardiology. 2014 Academic Article GET IT
Times cited: 24
Usefulness of the electrocardiogram in predicting cardiovascular mortality in asymptomatic adults with aortic stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis Study). The American journal of cardiology. 2014 Academic Article GET IT
Times cited: 6
Stroke in patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. Stroke. 2014 Academic Article GET IT
Times cited: 13
Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients. Circulation. Cardiovascular imaging. 2014 Academic Article GET IT
Times cited: 68
Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study. Journal of hypertension. 2014 Academic Article GET IT
Times cited: 15
Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study). Blood pressure. 2014 Academic Article GET IT
Times cited: 18
Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy. American journal of hypertension. 2014 Academic Article GET IT
Times cited: 6
New-onset atrial fibrillation is associated with cardiovascular events leading to death in a first time myocardial infarction population of 89,703 patients with long-term follow-up: a nationwide study. Journal of the American Heart Association. 2014 Academic Article GET IT
Times cited: 59
Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study. Journal of hypertension. 2013 Academic Article GET IT
Times cited: 14
Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Circulation. Arrhythmia and electrophysiology. 2013 Academic Article GET IT
Times cited: 50
Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: the LIFE study. American journal of hypertension. 2013 Academic Article GET IT
Times cited: 22
Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. Hypertension (Dallas, Tex. : 1979). 2012 Academic Article GET IT
Times cited: 51
Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study. American journal of hypertension. 2012 Academic Article GET IT
Times cited: 20
Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study. American journal of hypertension. 2012 Academic Article GET IT
Times cited: 6
Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Journal of hypertension. 2012 Academic Article GET IT
Times cited: 6
Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy. American journal of hypertension. 2012 Academic Article GET IT
Times cited: 21
Impact of QRS duration and morphology on the risk of sudden cardiac death in asymptomatic patients with aortic stenosis: the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study. Journal of the American College of Cardiology. 2012 Academic Article GET IT
Times cited: 30
Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. Circulation. 2011 Academic Article GET IT
Times cited: 48
Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study. Blood pressure. 2011 Academic Article GET IT
Times cited: 11
In-treatment stroke volume predicts cardiovascular risk in hypertension. Journal of hypertension. 2011 Academic Article GET IT
Times cited: 12
Impact of overweight and obesity on cardiac benefit of antihypertensive treatment. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2011 Academic Article GET IT
Times cited: 24
Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy. Journal of hypertension. 2011 Academic Article GET IT
Times cited: 5
Aortic root geometry in aortic stenosis patients (a SEAS substudy). European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology. 2011 Academic Article GET IT
Times cited: 13
Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study). The American journal of cardiology. 2010 Academic Article GET IT
Times cited: 34
In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. Journal of hypertension. 2010 Academic Article GET IT
Times cited: 27
Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. Journal of hypertension. 2010 Academic Article GET IT
Times cited: 18
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Blood pressure. 2010 Academic Article GET IT
Times cited: 54
Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study. Blood pressure. 2010 Academic Article GET IT
Times cited: 1
Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study. Journal of human hypertension. 2010 Academic Article GET IT
Times cited: 15
Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. American journal of hypertension. 2010 Academic Article GET IT
Times cited: 26
Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during antihypertensive treatment (from the LIFE echo-substudy). The American journal of cardiology. 2009 Academic Article GET IT
Times cited: 17
Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2009 Academic Article GET IT
Times cited: 25
Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. 2009 Academic Article GET IT
Times cited: 21
Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy. JACC. Cardiovascular imaging. 2009 Academic Article GET IT
Times cited: 176
Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2009 Academic Article GET IT
Times cited: 22
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Journal of hypertension. 2009 Academic Article GET IT
Times cited: 29
Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study). Blood pressure. 2009 Academic Article GET IT
Times cited: 10
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Circulation. Arrhythmia and electrophysiology. 2008 Academic Article GET IT
Times cited: 53
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study. American heart journal. 2008 Academic Article GET IT
Times cited: 10
The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy. Therapeutic advances in cardiovascular disease. 2008 Review GET IT
Times cited: 15
Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of hypertension. 2008 Academic Article GET IT
Times cited: 15
Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. Journal of hypertension. 2008 Academic Article GET IT
Times cited: 24
Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology. 2008 Academic Article GET IT
Times cited: 120
Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study. American journal of hypertension. 2008 Academic Article GET IT
Times cited: 6
Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of hypertension. 2008 Academic Article GET IT
Times cited: 9
Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension (Dallas, Tex. : 1979). 2008 Academic Article GET IT
Times cited: 78
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. American journal of hypertension. 2008 Academic Article GET IT
Times cited: 19
The effect of angiotensin receptor blockers for preventing atrial fibrillation. Current hypertension reports. 2007 Review GET IT
Times cited: 1
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation. 2007 Academic Article GET IT
Times cited: 162
Electrocardiographic and echocardiographic detection of myocardial infarction in patients with left-ventricular hypertrophy. The LIFE Study. American journal of hypertension. 2007 Academic Article GET IT
Times cited: 5
Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. Journal of human hypertension. 2007 Academic Article GET IT
Times cited: 42
Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. Journal of hypertension. 2007 Academic Article GET IT
Times cited: 19
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. Journal of hypertension. 2007 Academic Article GET IT
Times cited: 20
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial. Hypertension (Dallas, Tex. : 1979). 2006 Academic Article GET IT
Times cited: 185
Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of hypertension. 2006 Academic Article GET IT
Times cited: 17
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA. 2006 Academic Article GET IT
Times cited: 211
Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation. Current cardiology reports. 2006 Review GET IT
Times cited: 6
N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy. Journal of hypertension. 2006 Academic Article GET IT
Times cited: 34
The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study. Journal of human hypertension. 2006 Letter GET IT
Times cited: 5
Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. Journal of hypertension. 2006 Academic Article GET IT
Times cited: 77
Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study. Hypertension (Dallas, Tex. : 1979). 2006 Academic Article GET IT
Times cited: 10
Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. Blood pressure. 2006 Academic Article GET IT
Times cited: 10
Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy. American journal of hypertension. 2005 Academic Article GET IT
Times cited: 22
Black pearl in the LIFE study: angiotensin-II receptor blockade on atrial fibrillation for future personalized medicine. Journal of the American College of Cardiology. 2005 Letter GET IT
Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. Hypertension (Dallas, Tex. : 1979). 2005 Academic Article GET IT
Times cited: 20
Impairment of cardiac function in hypertensive patients with Type 2 diabetes: a LIFE study. Diabetic medicine : a journal of the British Diabetic Association. 2005 Academic Article GET IT
Times cited: 11
Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. Journal of hypertension. 2005 Academic Article GET IT
Times cited: 38
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation. 2005 Academic Article GET IT
Times cited: 34
Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. Journal of hypertension. 2005 Academic Article GET IT
Times cited: 55
Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: a LIFE substudy. Journal of human hypertension. 2005 Academic Article GET IT
Times cited: 31
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. Journal of the American College of Cardiology. 2005 Academic Article GET IT
Times cited: 695
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. Journal of the American College of Cardiology. 2005 Academic Article GET IT
Times cited: 198
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (Dallas, Tex. : 1979). 2005 Academic Article GET IT
Times cited: 496
Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE Study). The American journal of cardiology. 2005 Academic Article GET IT
Times cited: 8
Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy). The American journal of cardiology. 2005 Academic Article GET IT
Times cited: 68
Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood pressure. 2005 Academic Article GET IT
Times cited: 46
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension (Dallas, Tex. : 1979). 2004 Academic Article GET IT
Times cited: 81
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004 Academic Article GET IT
Times cited: 661
Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). The American journal of cardiology. 2004 Academic Article GET IT
Times cited: 26
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. Journal of hypertension. 2004 Academic Article GET IT
Times cited: 117
Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. American heart journal. 2004 Academic Article GET IT
Times cited: 19
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004 Academic Article GET IT
Times cited: 380
N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. Journal of hypertension. 2004 Academic Article GET IT
Times cited: 88
24-h Ambulatory blood pressure in patients with ECG-determined left ventricular hypertrophy: left ventricular geometry and urinary albumin excretion-a LIFE substudy. Journal of human hypertension. 2004 Academic Article GET IT
Times cited: 13
Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy. Journal of human hypertension. 2004 Academic Article GET IT
Times cited: 55
Association between vascular dysfunction and reduced myocardial flow reserve in patients with hypertension: a LIFE substudy. Journal of human hypertension. 2004 Academic Article GET IT
Times cited: 27
Association of left bundle branch block with left ventricular structure and function in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of human hypertension. 2004 Academic Article GET IT
Times cited: 16
Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study). Journal of human hypertension. 2004 Academic Article GET IT
Times cited: 15
Impact of valvular regurgitation on left ventricular geometry and function in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of human hypertension. 2004 Academic Article GET IT
Times cited: 13
Is inappropriate left ventricular mass related to neurohormonal factors and/or arterial changes in hypertension? A LIFE substudy. Journal of human hypertension. 2004 Academic Article GET IT
Times cited: 8
Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study. Journal of human hypertension. 2004 Academic Article GET IT
Times cited: 30
Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study. Journal of human hypertension. 2004 Academic Article GET IT
Times cited: 24
Usefulness of the assessment of the appropriateness of left ventricular mass to detect left ventricular systolic and diastolic abnormalities in absence of echocardiographic left ventricular hypertrophy: the LIFE study. Journal of human hypertension. 2004 Academic Article GET IT
Times cited: 11
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Annals of internal medicine. 2003 Academic Article GET IT
Times cited: 465
Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study. American heart journal. 2003 Academic Article GET IT
Times cited: 32
Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study. Journal of hypertension. 2003 Academic Article GET IT
Times cited: 63
Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment. American journal of hypertension. 2003 Academic Article GET IT
Times cited: 9
Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. Hypertension (Dallas, Tex. : 1979). 2003 Academic Article GET IT
Times cited: 31
Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. American heart journal. 2002 Academic Article GET IT
Times cited: 59
Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. American heart journal. 2002 Academic Article GET IT
Times cited: 48
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. Journal of hypertension. 2002 Academic Article GET IT
Times cited: 369
A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention For Endpoint reduction. Journal of human hypertension. 2002 Academic Article GET IT
Times cited: 26
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation. 2002 Academic Article GET IT
Times cited: 62
Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. Journal of hypertension. 2002 Academic Article GET IT
Times cited: 68
Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation. 2002 Academic Article GET IT
Times cited: 165
Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension (Dallas, Tex. : 1979). 2002 Academic Article GET IT
Times cited: 192
Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Journal of hypertension. 2002 Academic Article GET IT
Times cited: 137
Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). The American journal of cardiology. 2002 Academic Article GET IT
Times cited: 16
Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). The American journal of cardiology. 2002 Academic Article GET IT
Times cited: 53
Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. American heart journal. 2002 Academic Article GET IT
Times cited: 129
Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. Journal of hypertension. 2001 Academic Article GET IT
Times cited: 105
Endothelial dysfunction in resistance arteries is related to high blood pressure and circulating low density lipoproteins in previously treated hypertension. American journal of hypertension. 2001 Academic Article GET IT
Times cited: 11
Similar effects of isolated systolic and combined hypertension on left ventricular geometry and function: the LIFE Study. American journal of hypertension. 2001 Academic Article GET IT
Times cited: 14
Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study. American heart journal. 2001 Academic Article GET IT
Times cited: 66
Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood pressure. 2001 Academic Article GET IT
Times cited: 102
Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint. The American journal of cardiology. 2001 Academic Article GET IT
Times cited: 63
Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Losartan Intervention For Endpoint Reduction in Hypertension Study. Journal of hypertension. 2001 Academic Article GET IT
Times cited: 45
Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension. Journal of hypertension. 2000 Academic Article GET IT
Times cited: 62
Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint. The American journal of cardiology. 2000 Academic Article GET IT
Times cited: 144
Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population : the LIFE study. Hypertension (Dallas, Tex. : 1979). 2000 Academic Article GET IT
Times cited: 200
Relative influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension. ICARUS, a LIFE sub study. Insulin Carotids US Scandinavia. Journal of hypertension. 2000 Academic Article GET IT
Times cited: 33

more ...

less ...

Background

education and training

M.D., Copenhagen University Faculty of Medicine (Denmark) 1992

Contact

full name

Kristian Wachtell

VIVO Weill Cornell Medical College

Kristian Wachtell Visiting Instructor in Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name